BioNTech’s (BNTX) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reissued their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Tuesday morning,MarketScreener reports.

Other research analysts have also recently issued reports about the company. Wells Fargo & Company set a $150.00 price objective on BioNTech and gave the stock an “overweight” rating in a research report on Tuesday, August 5th. JPMorgan Chase & Co. reduced their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Morgan Stanley reiterated an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday, November 12th. Finally, HC Wainwright raised their target price on shares of BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.20.

BioNTech Trading Up 3.0%

Shares of NASDAQ:BNTX opened at $102.70 on Tuesday. The firm has a market cap of $23.13 billion, a price-to-earnings ratio of -64.19 and a beta of 1.54. BioNTech has a 12 month low of $81.20 and a 12 month high of $129.27. The company’s fifty day simple moving average is $102.96 and its 200 day simple moving average is $105.00. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the company posted $0.81 EPS. BioNTech’s revenue for the quarter was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise bought a new position in shares of BioNTech in the 1st quarter valued at about $36,000. Financial Consulate Inc. acquired a new stake in BioNTech in the 3rd quarter valued at about $36,000. Huntington National Bank grew its holdings in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the period. LRI Investments LLC increased its position in BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after buying an additional 312 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.